Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CVM vs TARS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CVM Captures Overall Composite Edge (56.6 HOLD vs 39.5 SELL), While TARS Leads 3–2 on Growth & Valuation Pillars
CVM Overall Winner
6-Pillar Tally: CVM 2 – 3 TARS (1 Tie)
Matrix Metrics: CVM 6 – 4 TARS
As of Nov 16, 2026, Cel-Sci Corporation (CVM) captures the overall head-to-head institutional edge over Tarsus Pharmaceuticals, Inc. (TARS) on higher Unified Composite conviction (56.6/100 HOLD vs. 39.5/100 SELL) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while TARS wins 3–2 across the 6-pillar growth and valuation breakdown. CVM trades at $1.59 (23.0x Forward P/E, 0.0% operating margin) versus TARS at $77.83 (63.7x Forward P/E, -9.6% operating margin).
- Growth vs. Quality Trade-Off: CVM earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. TARS 39.5/100 SELL) and 0.65β · 120% Vol risk profile, whereas TARS leads top-line expansion (+63.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile TARS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CVM vs TARS
CVM
Head-to-Head Winner
Cel-Sci Corporation
$1.59
+24.22% 1D
Market Cap
$20.9M
TTM Revenue
$28,558
Forward P/E
23.0x
Beta / 30D Vol
0.65β · 120% Vol
Unified Composite Score
56.6
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
TARS
Tarsus Pharmaceuticals, Inc. Common Stock
$77.83
-3.06% 1D
Market Cap
$3.8B
TTM Revenue
$682M
Forward P/E
63.7x
Beta / 30D Vol
0.53β · 45% Vol
Unified Composite Score
39.5
SELL
Tech 15.0
Fund 44.0
Flow 68.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (CVM 2 – 3 TARS)
1. Valuation Multiples
CVM
Forward P/E
23.0x
63.7x
Trailing P/E
23.0x
63.7x
PEG Ratio
1.12x
N/M
EV / Revenue
N/M
5.5x
2. Growth & Scale
TARS
Revenue Growth (YoY)
-62.7%
+63.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$28,558
$682M
Market Cap
$20.9M
$3.8B
3. Profitability & Quality
CVM
Gross Margin
N/A
83.8%
Operating Margin
0.0%
-9.6%
Net Profit Margin
0.0%
-102.9%
Return on Equity (ROE)
-252.5%
-319.8%
4. Balance Sheet & Cash Flow
TARS
Cash Generation (TTM)
-$17M
-$4.8M
Cash Flow Margin
N/A
-0.7%
Net Cash / Leverage
$6.6M Net Debt (1.24x D/E)
$64M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
TARS
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
N/A (N/A)
67.5% (4th %ile)
Put/Call OI Skew
N/A
0.64x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CVM (6) vs TARS (4)| Institutional Metric | CVM | TARS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $20.9M | $3.8B | TARS | |
| Trailing P/E Ratio | 23.0x | 63.7x | CVM | |
| Forward P/E Ratio | 23.0x | 63.7x | CVM | |
| Revenue Growth (YoY) | -62.7% | +63.9% | TARS | |
| Operating Margin (TTM) | 0.0% | -9.6% | CVM | |
| Net Profit Margin | 0.0% | -102.9% | CVM | |
| Return on Equity (ROE) | -252.5% | -319.8% | CVM | |
| 52-Week Range Position | 10% ($1–$8) | 64% ($54–$92) | TARS | |
| Beta / 30D Volatility | 0.65β · 120% Vol | 0.53β · 45% Vol | TARS | |
| Unified Institutional Score | 56.6 / 100 (HOLD) | 39.5 / 100 (SELL) | CVM | |
| Trailing 12M Revenue (USD) | $28,558 | $682M | Scale | |
| Gross Profit Margin (TTM) | N/A | 83.8% | Quality | |
| PEG Ratio & EV / Revenue | 1.12x PEG · N/M EV/Rev | N/M PEG · 5.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$17M ($6.6M Net Debt (1.24x D/E)) | -$4.8M ($64M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
TARS +25.5 pp
3M Horizon
TARS +9.57 pp
6M Horizon
TARS +31.45 pp
1Y Horizon
TARS +82.71 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CVM Revenue | TARS Revenue | CVM Op. Margin | TARS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2012 | $0M | N/A | -6772.3% | N/A | CVM |
| FY2013 | $0M | N/A | -12450.1% | N/A | CVM |
| FY2014 | $0M | N/A | -9721.4% | N/A | CVM |
| FY2021 | N/A | $60M | N/A | -21.3% | TARS |
| FY2022 | N/A | $30M | N/A | -242.9% | TARS |
| FY2023 | N/A | $20M | N/A | -820.5% | TARS |
| FY2024 | N/A | $180M | N/A | -65.9% | TARS |
| FY2025 | N/A | $450M | N/A | -15.7% | TARS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CVM
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
TARS
CONSOLIDATION
Current IV
67.5%
IV Percentile
4th %ile
Put/Call OI Skew
0.64x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact TARS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CVM Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
TARS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CVM vs TARS Key Questions & Quantitative Answers
As of Nov 16, 2026, Cel-Sci Corporation (CVM) captures the overall head-to-head institutional edge over Tarsus Pharmaceuticals, Inc. (TARS) on higher Unified Composite conviction (56.6/100 HOLD vs. 39.5/100 SELL) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while TARS wins 3–2 across the 6-pillar growth and valuation breakdown. CVM trades at $1.59 (23.0x Forward P/E, 0.0% operating margin) versus TARS at $77.83 (63.7x Forward P/E, -9.6% operating margin). Growth vs. Quality Trade-Off: CVM earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. TARS 39.5/100 SELL) and 0.65β · 120% Vol risk profile, whereas TARS leads top-line expansion (+63.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile TARS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TARS leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with TARS at +63.9% YoY revenue growth and +0.0% YoY earnings growth on $682M TTM revenue (83.8% gross margin, -9.6% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), CVM cumulative revenue shifted N/A while TARS shifted +650.0%. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TARS.
CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas TARS trades at 63.7x Forward P/E, 63.7x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (-0.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus TARS (-319.8% ROE) capital efficiency.
In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk). By comparison, TARS carries 67.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.64x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.53β · 45% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
TARS vs CVM · Reverse Pair
CVM vs AGEN
· Sector Peer
CVM vs BCRX
· Sector Peer
TARS vs PHAT
· Sector Peer
TARS vs EWTX
· Sector Peer
TARS vs STOK
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem